Open Nav

Market Outlook – IPOs Ascendant and Watching M&A Valuations

  • Rajeev Dadoo, S.R. One Limited,
  • Anna French, Qiming Venture Partners USA,
  • Ken Haas, Abingworth,
  • Matt McAviney, NEA,
  • Jimmy Z. Zhang, LAV (Lilly Asian Ventures),
  • Gregory Wade, BTIG

Despite heightened political discussion of the value of marketed medicines, the biopharma investor community continues to increase its support. As the industry has gained traction on new drug approvals through 2018, the financial dollars have followed with record public and private offerings. The attractive IPO market has however resulted in fewer M&A deals than prior years, with high pre-money IPO valuations for later-stage companies making it less enticing for them to accept early-exit offers. This has led to an M&A shift to focus on early-stage companies. The session will examine the current deals and market trends while highlighting the path forward.

  • Date:Thursday, October 18
  • Time:4:00 PM - 4:55 PM
  • Session Type:Educational Session
Rajeev Dadoo
S.R. One Limited
Anna French
Qiming Venture Partners USA
Ken Haas
Matt McAviney
Jimmy Z. Zhang
LAV (Lilly Asian Ventures)
Gregory Wade